Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Schizophrenia"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 310069

Starter badań:

Tytuł:
Long-term outcomes of deep brain stimulation for treatment-resistant schizophrenia: Exploring potential targets.
Autorzy:
Aibar-Durán JÁ; Department of Neurosurgery, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Corripio Collado I; Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.
Roldán Bejarano A; Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain. Electronic address: .
Sánchez Nevado R; Department of Neurosurgery, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Aracil Bolanos I; Deparment of Neurology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
García-Cornet J; Ingeniering imaging and Signaling, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Alonso-Solís A; Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.
Grasa Bello EM; Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.
de Quintana Schmidt C; Department of Neurosurgery, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Muñoz Hernández F; Department of Neurosurgery, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Molet Teixidó J; Department of Neurosurgery, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Rodríguez RR; Department of Neurosurgery, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Pokaż więcej
Źródło:
Journal of psychiatric research [J Psychiatr Res] 2023 Jul; Vol. 163, pp. 296-304. Date of Electronic Publication: 2023 May 18.
Typ publikacji:
Journal Article
MeSH Terms:
Schizophrenia*/therapy
Schizophrenia*/etiology
Deep Brain Stimulation*/methods
Male ; Humans ; Female ; Schizophrenia, Treatment-Resistant ; Nucleus Accumbens/diagnostic imaging ; Parietal Lobe
Czasopismo naukowe
Szczegóły
Tytuł:
Inflammatory disequilibrium and lateral ventricular enlargement in treatment-resistant schizophrenia.
Autorzy:
Chen W; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Gou M; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Wang L; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Li N; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Li W; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Tong J; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Zhou Y; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Xie T; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Yu T; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Feng W; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Li Y; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Chen S; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Tian B; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Tan S; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Wang Z; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Pan S; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Luo X; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Zhang P; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Huang J; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Tian L; Institute of Biomedicine and Translational Medicine, Department of Physiology, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Li CR; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Tan Y; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China. Electronic address: .
Pokaż więcej
Źródło:
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology [Eur Neuropsychopharmacol] 2023 Jul; Vol. 72, pp. 18-29. Date of Electronic Publication: 2023 Apr 13.
Typ publikacji:
Journal Article
MeSH Terms:
Schizophrenia*/diagnostic imaging
Schizophrenia*/drug therapy
Antipsychotic Agents*/therapeutic use
Humans ; Schizophrenia, Treatment-Resistant ; Cytokines ; Biomarkers
Czasopismo naukowe
Szczegóły
Tytuł:
Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia.
Autorzy:
Anand R; APC, St. Moritz, Switzerland.
Turolla A; Newron Pharmaceuticals SpA, Bresso, Italy.
Chinellato G; Newron Pharmaceuticals SpA, Bresso, Italy.
Roy A; CliniRx Research Pvt Ltd, New Delhi, India.
Hartman RD; NeurWrite LLC, Morristown, NJ, USA.
Pokaż więcej
Źródło:
The international journal of neuropsychopharmacology [Int J Neuropsychopharmacol] 2023 Aug 29; Vol. 26 (8), pp. 523-528.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antipsychotic Agents*/adverse effects
Schizophrenia*/chemically induced
Humans ; Glutamic Acid ; Schizophrenia, Treatment-Resistant
Czasopismo naukowe
Szczegóły
Tytuł:
The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia.
Autorzy:
Vellucci L; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
Ciccarelli M; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
Buonaguro EF; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
Fornaro M; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
D'Urso G; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
De Simone G; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
Iasevoli F; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
Barone A; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
de Bartolomeis A; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2023 Aug 05; Vol. 13 (8). Date of Electronic Publication: 2023 Aug 05.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Schizophrenia*/drug therapy
Psychotic Disorders*/drug therapy
Humans ; Schizophrenia, Treatment-Resistant ; Dopamine ; Neurobiology ; Glutamic Acid
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia.
Autorzy:
O'Connell KS; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: .
Koch E; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Lenk HÇ; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway.
Akkouh IA; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Hindley G; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Psychosis Studies, Institute of Psychiatry, Psychology and Neurosciences, King's College London, United Kingdom.
Jaholkowski P; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Smith RL; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
Holen B; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Shadrin AA; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; KG Jebsen Centre for Neurodevelopmental disorders, University of Oslo and Oslo University Hospital, Oslo, Norway.
Frei O; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Bioinformatics, Department of Informatics, University of Oslo, 0316 Oslo, Norway.
Smeland OB; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Steen NE; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Dale AM; Department of Radiology, University of California, San Diego, La Jolla, CA 92093, USA; Multimodal Imaging Laboratory, University of California San Diego, La Jolla, CA 92093, USA; Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA; Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA.
Molden E; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway.
Djurovic S; Department of Medical Genetics, Oslo University Hospital, Oslo, Norway; NORMENT Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.
Andreassen OA; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; KG Jebsen Centre for Neurodevelopmental disorders, University of Oslo and Oslo University Hospital, Oslo, Norway. Electronic address: .
Pokaż więcej
Źródło:
Psychiatry research [Psychiatry Res] 2023 Jul; Vol. 325, pp. 115217. Date of Electronic Publication: 2023 Apr 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Schizophrenia*/drug therapy
Schizophrenia*/genetics
Clozapine*/pharmacology
Clozapine*/therapeutic use
Antipsychotic Agents*/pharmacology
Antipsychotic Agents*/therapeutic use
Humans ; Schizophrenia, Treatment-Resistant ; Body Mass Index ; Genome-Wide Association Study
Czasopismo naukowe
Szczegóły
Tytuł:
Long-term outcomes of delayed clozapine initiation in treatment-resistant schizophrenia: a multicenter retrospective cohort study.
Autorzy:
Hatano M; Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi, Japan. .; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan. .
Kamei H; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Takeuchi I; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan.; Department of Psychiatry, Okehazama Hospital, Toyoake, Japan.
Gomi K; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan.; Nagano Prefectural Mental Wellness Center Komagane, Komagane, Japan.
Sakakibara T; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan.; Department of Psychiatry, Holy Cross Hospital, Toki, Japan.
Hotta S; Department of Hospital Pharmacy, Nagoya University School of Medicine, Nagoya, Japan.; Division of Clinical Sciences and Neuropsychopharmacology, Graduate School of Pharmacy, Meijo University, Nagoya, Japan.
Esumi S; Department of Pharmacy, Okayama University Hospital, Okayama, Japan.; The Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan.
Tsubouchi K; Department of Hospital Pharmacy, Kanazawa University, Kanazawa, Japan.
Shimizu Y; Department of Pharmacy, Kanazawa Medical University Hospital, Kahoku, Japan.
Yamada S; Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi, Japan.
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2023 Sep 15; Vol. 23 (1), pp. 673. Date of Electronic Publication: 2023 Sep 15.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Clozapine*/therapeutic use
Schizophrenia*/drug therapy
Humans ; Schizophrenia, Treatment-Resistant ; Prospective Studies ; Retrospective Studies
Czasopismo naukowe
Szczegóły
Tytuł:
Significant improvement of psychotic symptoms in treatment-resistant schizophrenia with clozapine in an adolescent with SHINE syndrome: a case report.
Autorzy:
Yang M; University of Arizona College of Medicine - Phoenix, Phoenix, AZ, 85004, USA. .
Rubin A; Phoenix Children's Hospital, Phoenix, AZ, 85016, USA.
Wondimu R; Phoenix Children's Hospital, Phoenix, AZ, 85016, USA.
Grebe T; Phoenix Children's Hospital, Phoenix, AZ, 85016, USA.
Ritfeld G; Phoenix Children's Hospital, Phoenix, AZ, 85016, USA.
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2023 Jun 29; Vol. 23 (1), pp. 483. Date of Electronic Publication: 2023 Jun 29.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Clozapine*/therapeutic use
Schizophrenia*/complications
Schizophrenia*/drug therapy
Psychotic Disorders*/complications
Psychotic Disorders*/drug therapy
Antipsychotic Agents*/therapeutic use
Female ; Humans ; Adolescent ; Child ; Schizophrenia, Treatment-Resistant ; Syndrome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A case study of the utilization of clozapine treatment for treatment-resistant schizophrenia associated with 22q11.2 deletion syndrome.
Autorzy:
Tsurue A; Miyakonojo Shinsei Hospital, Miyakonojo, Japan.; Department of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Funahashi H; Department of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Tsurue K; Miyakonojo Shinsei Hospital, Miyakonojo, Japan.
Kawano M; Miyakonojo Shinsei Hospital, Miyakonojo, Japan.
Ishida Y; Department of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Hirano Y; Department of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Pokaż więcej
Źródło:
Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2023 Jun; Vol. 43 (2), pp. 272-276. Date of Electronic Publication: 2023 Mar 16.
Typ publikacji:
Case Reports
MeSH Terms:
DiGeorge Syndrome*/complications
DiGeorge Syndrome*/drug therapy
DiGeorge Syndrome*/genetics
Schizophrenia*/complications
Schizophrenia*/drug therapy
Schizophrenia*/genetics
Clozapine*/therapeutic use
Humans ; Female ; Adolescent ; Adult ; Schizophrenia, Treatment-Resistant ; Genetic Testing
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Identification of novel functional brain proteins for treatment-resistant schizophrenia: Based on a proteome-wide association study.
Autorzy:
Wei W; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Zhang H; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Cheng B; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Qin X; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
He D; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Zhang N; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Zhao Y; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Cai Q; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Shi S; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Chu X; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Wen Y; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Liu H; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Jia Y; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Zhang F; 1Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.; 2Department of Psychiatry, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Pokaż więcej
Źródło:
European psychiatry : the journal of the Association of European Psychiatrists [Eur Psychiatry] 2023 Apr 14; Vol. 66 (1), pp. e33. Date of Electronic Publication: 2023 Apr 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Schizophrenia*/drug therapy
Schizophrenia*/genetics
Humans ; Proteome/genetics ; Schizophrenia, Treatment-Resistant ; Genome-Wide Association Study ; Reactive Oxygen Species/therapeutic use ; Brain/metabolism
Czasopismo naukowe
Szczegóły
Tytuł:
Sex differences in the association of treatment-resistant schizophrenia and serum interleukin-6 levels.
Autorzy:
He J; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.
Wei Y; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Department of Psychiatry, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Li J; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Affiliated Wuhan Mental Health Center, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Tang Y; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.
Liu J; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Xiangya Nursing School of Central South University, Changsha, China.
He Z; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.; School of Mental Health, Wenzhou Medical University, Wenzhou, China.
Zhou R; The Ninth Hospital of Changsha, Changsha, China.
He X; The Ninth Hospital of Changsha, Changsha, China.
Ren H; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Department of Psychiatry, Shandong Provincial Hospital, Shandong University, Jinan, China.
Liao Y; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Gu L; RIKEN Center for Advanced Intelligence Project, Tokyo, Japan.; Research Center for Advanced Science and Technology (RCAST), University of Tokyo, Tokyo, Japan.
Yuan N; Hunan Provincial Brain Hospital (The Second People's Hospital of Hunan Province), Changsha, China. .
Chen X; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China. .
Tang J; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China. .; Zigong Mental Health Center, Zigong, China. .
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2023 Jun 27; Vol. 23 (1), pp. 470. Date of Electronic Publication: 2023 Jun 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Schizophrenia*/drug therapy
Female ; Humans ; Male ; Inflammation ; Interleukin-6 ; Schizophrenia, Treatment-Resistant ; Sex Characteristics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Exploration of the role of emotional expression of treatment-resistant schizophrenia patients having followed virtual reality therapy: a content analysis.
Autorzy:
Hudon A; Centre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada.; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Lammatteo V; Université de Montréal, Montréal, Qc, Canada.
Rodrigues-Coutlée S; Université de Montréal, Montréal, Qc, Canada.
Dellazizzo L; Centre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada.; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Giguère S; Centre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada.; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Phraxayavong K; Services et Recherches Psychiatriques AD, Montreal, QC, Canada.
Potvin S; Centre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada.; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Dumais A; Centre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada. .; Services et Recherches Psychiatriques AD, Montreal, QC, Canada. .; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada. .; Institut national de psychiatrie légale Philippe-Pinel, Montreal, Canada. .
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2023 Jun 12; Vol. 23 (1), pp. 420. Date of Electronic Publication: 2023 Jun 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Schizophrenia*
Virtual Reality Exposure Therapy*
Humans ; Schizophrenia, Treatment-Resistant ; Emotions ; Anger
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Enhanced L-β-Aminoisobutyric Acid Is Involved in the Pathophysiology of Effectiveness for Treatment-Resistant Schizophrenia and Adverse Reactions of Clozapine.
Autorzy:
Fukuyama K; Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan.
Motomura E; Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan.
Okada M; Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2023 May 19; Vol. 13 (5). Date of Electronic Publication: 2023 May 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Clozapine*/adverse effects
Antipsychotic Agents*/adverse effects
Schizophrenia*/metabolism
Receptors, Metabotropic Glutamate*/metabolism
Rats ; Animals ; Dizocilpine Maleate/pharmacology ; Glutamic Acid/metabolism ; Schizophrenia, Treatment-Resistant ; Rats, Sprague-Dawley ; Prefrontal Cortex/metabolism ; Receptors, Glutamate ; Receptors, GABA-A/metabolism ; gamma-Aminobutyric Acid/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Stage-Specific Brain Aging in First-Episode Schizophrenia and Treatment-Resistant Schizophrenia.
Autorzy:
Kim WS; Department of Psychiatry, Jeonbuk National University, Medical School, Jeonju, Korea.
Heo DW; Department of Brain and Cognitive Engineering, Korea University, Seoul, Korea.; Department of Artificial Intelligence, Korea University, Seoul, Korea.
Shen J; Department of Psychiatry, Jeonbuk National University, Medical School, Jeonju, Korea.; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.
Tsogt U; Department of Psychiatry, Jeonbuk National University, Medical School, Jeonju, Korea.; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.
Odkhuu S; Department of Psychiatry, Jeonbuk National University, Medical School, Jeonju, Korea.; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.
Kim SW; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.; Department of Psychiatry, Chonnam National University Medical School, Gwangju, Korea.
Suk HI; Department of Brain and Cognitive Engineering, Korea University, Seoul, Korea.; Department of Artificial Intelligence, Korea University, Seoul, Korea.
Ham BJ; Department of Psychiatry, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Rami FZ; Department of Psychiatry, Jeonbuk National University, Medical School, Jeonju, Korea.; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.
Kang CY; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.
Sui J; Tri-Institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Georgia Institute of Technology, Emory University, Atlanta, Georgia, USA.; State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing, China.
Chung YC; Department of Psychiatry, Jeonbuk National University, Medical School, Jeonju, Korea.; Department of Psychiatry, Jeonbuk National University Hospital, Jeonju, Korea.; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.
Pokaż więcej
Źródło:
The international journal of neuropsychopharmacology [Int J Neuropsychopharmacol] 2023 Mar 22; Vol. 26 (3), pp. 207-216.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Schizophrenia*/diagnostic imaging
Schizophrenia*/drug therapy
Humans ; Schizophrenia, Treatment-Resistant ; Brain ; Aging/physiology ; Magnetic Resonance Imaging/methods
Czasopismo naukowe
Szczegóły
Tytuł:
Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review.
Autorzy:
Ying J; East Region, Institute of Mental Health, Singapore 539747, Singapore.
Chew QH; Research Division, Institute of Mental Health, Singapore 539747, Singapore.
McIntyre RS; Department of PsychiSatry, University of Toronto, Toronto, ON M5R 0A3, Canada.; Brain and Cognition Discovery Foundation Toronto, Toronto, ON M4W 3W4, Canada.
Sim K; West Region, Institute of Mental Health, Singapore 539747, Singapore.
Pokaż więcej
Źródło:
Genes [Genes (Basel)] 2023 Mar 10; Vol. 14 (3). Date of Electronic Publication: 2023 Mar 10.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Clozapine*/adverse effects
Schizophrenia*/drug therapy
Schizophrenia*/genetics
Antipsychotic Agents*/adverse effects
Psychiatry*
Drug-Related Side Effects and Adverse Reactions*
Humans ; Schizophrenia, Treatment-Resistant ; Quality of Life
Czasopismo naukowe
Szczegóły
Tytuł:
Genome-wide methylation analysis of treatment resistant schizophrenia.
Autorzy:
De Luca V; Department of Psychiatry, CAMH, University of Toronto, 250 College St, Toronto, M5T1R8, Canada. .
Chaudhary Z; Department of Psychiatry, CAMH, University of Toronto, 250 College St, Toronto, M5T1R8, Canada.
Al-Chalabi N; Department of Psychiatry, CAMH, University of Toronto, 250 College St, Toronto, M5T1R8, Canada.
Qian J; Department of Psychiatry, CAMH, University of Toronto, 250 College St, Toronto, M5T1R8, Canada.
Borlido C; Department of Psychiatry, CAMH, University of Toronto, 250 College St, Toronto, M5T1R8, Canada.
Gerretsen P; Department of Psychiatry, CAMH, University of Toronto, 250 College St, Toronto, M5T1R8, Canada.
Graff A; Department of Psychiatry, CAMH, University of Toronto, 250 College St, Toronto, M5T1R8, Canada.
Remington G; Department of Psychiatry, CAMH, University of Toronto, 250 College St, Toronto, M5T1R8, Canada.
Chintoh A; Department of Psychiatry, CAMH, University of Toronto, 250 College St, Toronto, M5T1R8, Canada.
Pokaż więcej
Źródło:
Journal of neural transmission (Vienna, Austria : 1996) [J Neural Transm (Vienna)] 2023 Feb; Vol. 130 (2), pp. 165-169. Date of Electronic Publication: 2023 Jan 17.
Typ publikacji:
Journal Article
MeSH Terms:
Schizophrenia*/drug therapy
Schizophrenia*/genetics
Antipsychotic Agents*/therapeutic use
Humans ; Schizophrenia, Treatment-Resistant ; Pilot Projects ; DNA Methylation ; Epigenesis, Genetic ; Genome-Wide Association Study
Czasopismo naukowe
Szczegóły
Tytuł:
MiRNA Differences Related to Treatment-Resistant Schizophrenia.
Autorzy:
Pérez-Rodríguez D; NeuroEpigenetics Lab, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain.; Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, 36213 Vigo, Spain.
Penedo MA; Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, 36213 Vigo, Spain.; Grupo de Neurofarmacología de Las Adicciones y Los Trastornos Degenerativos (NEUROFAN), Universidad CEU San Pablo, 28925 Madrid, Spain.
Rivera-Baltanás T; Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, 36213 Vigo, Spain.
Peña-Centeno T; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, 37075 Göttingen, Germany.
Burkhardt S; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, 37075 Göttingen, Germany.
Fischer A; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, 37075 Göttingen, Germany.
Prieto-González JM; NeuroEpigenetics Lab, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain.; Servicio de Neurología, Hospital Clínico Universitario de Santiago, 15706 Santiago de Compostela, Spain.; Grupo Trastornos del Movimiento, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain.
Olivares JM; Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, 36213 Vigo, Spain.; Department of Psychiatry, Área Sanitaria de Vigo, 36312 Vigo, Spain.
López-Fernández H; SING Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36213 Vigo, Spain.; CINBIO, Department of Computer Science, ESEI-Escuela Superior de Ingeniería Informática, Universidade de Vigo, 32004 Ourense, Spain.
Agís-Balboa RC; NeuroEpigenetics Lab, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain.; Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, 36213 Vigo, Spain.; Servicio de Neurología, Hospital Clínico Universitario de Santiago, 15706 Santiago de Compostela, Spain.; Grupo Trastornos del Movimiento, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jan 18; Vol. 24 (3). Date of Electronic Publication: 2023 Jan 18.
Typ publikacji:
Journal Article
MeSH Terms:
Schizophrenia*/drug therapy
Schizophrenia*/genetics
Schizophrenia*/diagnosis
MicroRNAs*/genetics
MicroRNAs*/therapeutic use
Antipsychotic Agents*/pharmacology
Antipsychotic Agents*/therapeutic use
Humans ; Schizophrenia, Treatment-Resistant ; Drug Resistance/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Decreased cortical gyrification and surface area in the left medial parietal cortex in patients with treatment-resistant and ultratreatment-resistant schizophrenia.
Autorzy:
Kitajima K; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tamura S; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Sasabayashi D; Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.; Research Center for Idling Brain Science, University of Toyama, Toyama, Japan.
Nakajima S; Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Iwata Y; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.; Department of Neuropsychiatry, University of Yamanashi Faculty of Medicine, Yamanashi, Japan.
Ueno F; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Takai Y; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takahashi J; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Department of Neuropsychiatry, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Caravaggio F; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Mar W; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Torres-Carmona E; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Noda Y; Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.
Gerretsen P; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Luca V; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Mimura M; Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.
Hirano S; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Nakao T; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Onitsuka T; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Remington G; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Graff-Guerrero A; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Hirano Y; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Institute of Industrial Science, The University of Tokyo, Tokyo, Japan.
Pokaż więcej
Źródło:
Psychiatry and clinical neurosciences [Psychiatry Clin Neurosci] 2023 Jan; Vol. 77 (1), pp. 2-11. Date of Electronic Publication: 2022 Oct 27.
Typ publikacji:
Journal Article
MeSH Terms:
Schizophrenia*/diagnostic imaging
Schizophrenia*/drug therapy
Schizophrenia*/pathology
Clozapine*/pharmacology
Clozapine*/therapeutic use
Humans ; Parietal Lobe ; Magnetic Resonance Imaging ; Schizophrenia, Treatment-Resistant ; Cerebral Cortex
Czasopismo naukowe
Szczegóły
Tytuł:
Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.
Autorzy:
de Bartolomeis A; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples 'Federico II', 80131 Naples, Italy.
Ciccarelli M; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples 'Federico II', 80131 Naples, Italy.
De Simone G; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples 'Federico II', 80131 Naples, Italy.
Mazza B; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples 'Federico II', 80131 Naples, Italy.
Barone A; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples 'Federico II', 80131 Naples, Italy.
Vellucci L; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples 'Federico II', 80131 Naples, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Mar 21; Vol. 24 (6). Date of Electronic Publication: 2023 Mar 21.
Typ publikacji:
Systematic Review; Journal Article; Review
MeSH Terms:
Antipsychotic Agents*/pharmacology
Antipsychotic Agents*/therapeutic use
Schizophrenia*/drug therapy
Humans ; Dopamine/therapeutic use ; Schizophrenia, Treatment-Resistant ; beta-Arrestins
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials.
Autorzy:
Siafis S; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
Schneider-Thoma J; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany .
Hamza T; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.; Graduate School of Health Sciences, University of Bern, Bern, Switzerland.
Bighelli I; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
Dong S; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
Hansen WP; BASTA - Bündnis für psychisch erkrankte Menschen, Munich, Germany.
Davis JM; Psychiatric Institute, University of Illinois at Chicago, Chicago, Illinois, USA.; Department of Psychiatry, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Salanti G; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Leucht S; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
Pokaż więcej
Źródło:
BMJ open [BMJ Open] 2023 Feb 21; Vol. 13 (2), pp. e064504. Date of Electronic Publication: 2023 Feb 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antipsychotic Agents*/therapeutic use
Clozapine*/therapeutic use
Schizophrenia*/drug therapy
Humans ; Schizophrenia, Treatment-Resistant ; Patients ; Systematic Reviews as Topic ; Meta-Analysis as Topic
Czasopismo naukowe
Szczegóły
Tytuł:
Combination of two long-acting injectable antipsychotics in treatment-resistant schizophrenia: A retrospective 12-month mirror-image study.
Autorzy:
Calvin N; Univ. Grenoble Alpes, France.
Minischetti L; Department of Pharmacy, CH Alpes-Isère, F-38000 Saint-Egrève, France.
Salanon F; Department of Pharmacy, CH Alpes-Isère, F-38000 Saint-Egrève, France.
Llorca PM; University Clermont Auvergne, CMP-B CHU, CNRS, Clermont Auvergne INP, Institut Pascal, F-63000 Clermont-Ferrand, France.
Pouchon A; Univ. Grenoble Alpes, Inserm, CHU Grenoble Alpes, Grenoble Institut Neurosciences, 38000 Grenoble, France; Adult Psychiatry Department CHU Grenoble Alpes, 38000 Grenoble, France.
Polosan M; Univ. Grenoble Alpes, Inserm, CHU Grenoble Alpes, Grenoble Institut Neurosciences, 38000 Grenoble, France; Adult Psychiatry Department CHU Grenoble Alpes, 38000 Grenoble, France.
Dondé C; Univ. Grenoble Alpes, Inserm, CHU Grenoble Alpes, Grenoble Institut Neurosciences, 38000 Grenoble, France; Adult Psychiatry Department CHU Grenoble Alpes, 38000 Grenoble, France; Adult Psychiatry Department, CH Alpes-Isère, F-38000 Saint-Egrève, France. Electronic address: .
Pokaż więcej
Źródło:
Asian journal of psychiatry [Asian J Psychiatr] 2023 Feb; Vol. 80, pp. 103402. Date of Electronic Publication: 2022 Dec 13.
Typ publikacji:
Journal Article
MeSH Terms:
Antipsychotic Agents*/therapeutic use
Schizophrenia*/drug therapy
Humans ; Retrospective Studies ; Schizophrenia, Treatment-Resistant ; Delayed-Action Preparations/therapeutic use ; Administration, Oral ; Medication Adherence
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 310069

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies